Carregant...
Carregant...

Vés al contingut (premeu Retorn)

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia

Autor
Echeverria, P.; Bonjoch, A.; Puig, J.; Ornella, A.; Clotet, B.; Negredo, E.
Tipus d'activitat
Article en revista
Revista
HIV medicine
Data de publicació
2017-11-01
Volum
18
Número
10
Pàgina inicial
782
Pàgina final
786
DOI
https://doi.org/10.1111/hiv.12530 Obrir en finestra nova
URL
http://onlinelibrary.wiley.com/doi/10.1111/hiv.12530/pdf Obrir en finestra nova
Resum
Objectives: Cobicistat seems to have a low rate of adverse events compared with ritonavir. Methods: This restrospective observational study to evaluated changes in lipid parameters and the percentage of subjects with dyslipidemia in virologically suppressed HIV-infected patients who were receiving a regimen containing darunavir/ritonavir and were then switched from ritonavir to cobicistat, carried out from December 2015 to May 2016, included 299 HIV-1-infected patients who were on stable antiret...
Paraules clau
darunavir/cobicistat, darunavir/ritonavir, lipid profile, suppressed HIV-1-infected subjects

Participants

  • Echeverria Liras, Patricia  (autor)
  • Bonjoch Badia, Anna  (autor)
  • Puig, J.  (autor)
  • Ornella, A.  (autor)
  • Clotet Sala, Bonaventura  (autor)
  • Negredo Puigmal, Eugènia  (autor)